𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer

✍ Scribed by Naomi Haas; Bruce Roth; Carlos Garay; Gwen Yeslow; Michael Entmacher; Alan Weinstein; Andre Rogatko; James Babb; Carl Minnitti; David Flinker; Thomas Gillon; Gary Hudes

Book ID
117263636
Publisher
Elsevier Science
Year
2001
Tongue
English
Weight
174 KB
Volume
58
Category
Article
ISSN
0090-4295

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Multicenter Phase II study of estramusti
Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma
✍ David J. Vaughn; Archie W. Brown Jr.; W. Graydon Harker; Sang Huh; Lance Miller; πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 72 KB πŸ‘ 2 views

## Abstract ## BACKGROUND The current study determined the efficacy and toxicity of weekly paclitaxel in combination with estramustine phosphate (EMP) in patients with androgen‐independent prostate carcinoma (AIPC). ## METHODS Patients with progressive AIPC received 90 mg/m^2^ paclitaxel by 1‐ho

Weekly paclitaxel, estramustine phosphat
Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma : Results of a Minnie Pearl Cancer Research Network Phase II Trial
✍ Anthony A. Meluch; F. Anthony Greco; Lisa H. Morrissey; Eric L. Raefsky; Ronald πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 87 KB πŸ‘ 2 views

## Abstract ## BACKGROUND The objective of the current study was to evaluate the efficacy and toxicity of weekly paclitaxel, oral etoposide, and estramustine phosphate in the treatment of patients with advanced, hormone‐refractory prostate carcinoma. ## METHODS Patients with hormone‐refractory p